Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects
Li X, Bing Li, Meng Wang, Yi-Xiang Wang et autres
0 citationsAntimicrobial Agents and Chemotherapy
George Zhang
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
10Publications signalées
99Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Peptidase Inhibition and AnalysisProtein Degradation and InhibitorsNeuroblastoma Research and TreatmentsCOVID-19 Clinical Research StudiesMultiple Myeloma Research and Treatments
Publications récentes
Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study
Chong Wang, Fei Kong, Haibing Gao, Dachuan Cai et autres
8 citationsEClinicalMedicine
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Hongzhou Lu, George Zhang, John Mao, Xiaochun Chen et autres
23 citationsEClinicalMedicine
Supplementary Data from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
Supplementary Figure from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
Supplementary Figure from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
Supplementary Data from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
Data from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
Data from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
0 citations
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen et autres
68 citationsMolecular Cancer Therapeutics
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.